Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Common Equity (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Common Equity for 11 consecutive years, with $671.4 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 23.0% to $671.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $671.4 million through Dec 2025, down 23.0% year-over-year, with the annual reading at $671.4 million for FY2025, 23.0% down from the prior year.
  • Common Equity for Q4 2025 was $671.4 million at Intellia Therapeutics, down from $748.4 million in the prior quarter.
  • The five-year high for Common Equity was $1.2 billion in Q4 2022, with the low at $494.8 million in Q2 2021.
  • Average Common Equity over 5 years is $911.1 million, with a median of $958.2 million recorded in 2022.
  • The sharpest move saw Common Equity surged 235.87% in 2021, then decreased 26.34% in 2025.
  • Over 5 years, Common Equity stood at $1.0 billion in 2021, then grew by 18.78% to $1.2 billion in 2022, then dropped by 15.01% to $1.1 billion in 2023, then decreased by 16.97% to $872.0 million in 2024, then fell by 23.0% to $671.4 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $671.4 million, $748.4 million, and $715.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.